Fact sheet: BB Medtech

Fund information
Fund name
BB Medtech B EUR
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund managers
  • Stefan Blumsince 29/09/2009
  • John Manierisince 01/03/2016
  • Marcel Fritschsince 29/09/2009
Fund objective
The Fund invests worldwide in companies active in the medical technology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare systems as well as the expected market potential of a company's products and services. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is bottom-up.
Benchmark
  • MSCI Healthcare Equip. & Supp
Investment style
None
Investment method
Shares
Quick stats
1 Year return
20%
1 Year rank in sector
4/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
2.31%
Fund size
£129m (£139m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
119
Top in this sector
Fund name1 Year
BB Medtech20%
Pictet Health18.7%
Polar Capital Biotechnology18.6%
Variopartner SICAV MVGbMdtcF18.2%
Fidelity Gbl Health Care17.5%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA82.5%
    Denmark4.2%
    UK3.3%
    France3.1%
    Money Market1.8%
  • Health Care78.4%
    Others15.1%
    Biotechnology/Medical4.7%
    Money Market1.8%
  • US Equities82.5%
    Danish Equities4.2%
    UK Equities3.3%
    French Equities3.1%
    Money Market1.8%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund3.1%1.6%2.4%20%58.9%114.5%
Sector3.1%1.6%0%4.4%21.8%103.9%
Rank within sector17 / 3118 / 3110 / 314 / 312 / 2612 / 24
Quartile3rd3rd2nd1st1st2nd
Calendar performance
 YTD - 20172016201520142013
Fund4.2%6.5%10.9%35.4%15.5%
Sector4.3%-9.9%7.2%28.1%41%
Rank within sector16 / 313 / 319 / 2910 / 2624 / 24
Quartile3rd1st2nd2nd4th
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
11.45
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.69
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.95
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.17
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
10.27
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.87
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.63
Price movement
52 week high332.04
52 week low251.78
Current bid price-
Current offer price-
Current mid price328.68
Region
1USA82.5%
2Denmark4.2%
3UK3.3%
4France3.1%
5Money Market1.8%
6Germany1.7%
7New Zealand1.7%
8Canada1.2%
9Others0.5%
Industry sector
1Health Care78.4%
2Others15.1%
3Biotechnology/Medical4.7%
4Money Market1.8%
Asset type
1US Equities82.5%
2Danish Equities4.2%
3UK Equities3.3%
4French Equities3.1%
5Money Market1.8%
6German Equities1.7%
7New Zealand Equities1.7%
8Canadian Equities1.2%
9International Equities0.5%
Individual holdings
1ABBOTT LABORATORIES8.5%
2MEDTRONIC INC8.2%
3Boston Scientific Corp ORD7.1%
4STRYKER CORP5.7%
5ZIMMER BIOMET HLDGS INC4.9%
6EDWARDS LIFESCIENCES CORP4.8%
7BAXTER INTERNATIONAL INC4.2%
8DANAHER CORP4.2%
9GN STORE NORD3.7%
Management
Fund manager group
Bellevue Asset Management
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund objective
The Fund invests worldwide in companies active in the medical technology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare systems as well as the expected market potential of a company's products and services. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is bottom-up.
Benchmark
  • MSCI Healthcare Equip. & Supp
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Stefan Blum29/09/2009Stefan Blum is the Lead Portfolio Manager of the BB Medtech (Lux) Fund. He has 13 years of experience in the healthcare sector. Prior to joining Bellevue Asset Management he spent 4 years as head of investor relations at Sonova, the world's largest manufacturer of hearing instruments. As a financial analyst at Bank Sarasin from 1996 to 2000, he covered medical technology and other stocks. Before that he served as CFO of Obtree Technologies Inc. and advised Swiss listed companies on strategic investor relations issues. Stefan Blum obtained a degree in business administration/economics from the University of St. Gallen and is a graduate of AZEK.
John Manieri01/03/2016
Marcel Fritsch29/09/2009Marcel Fritsch is a Portfolio Manager of the BB Medtech (Lux) Fund. He was previously a consultant with Deloitte, a position he held for more than 3 years. In this function he provided multinational companies in medical technology, pharmaceutical and manufacturing sectors with support on strategic issues. Devising corporate strategy concepts, optimizing organizational structures and assessing the value of business entities in connection with corporate transactions were among his duties. Marcel Fritsch holds a degree in business administration/economics from the University of St. Gallen (HSG).
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Germany, Spain, United Kingdom, Luxembourg, Offshore
BB Medtech B CHF
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price233.36
CurrencyCHF
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX2
BB Medtech B EUR
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price328.68
CurrencyEUR
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX0
BB Medtech B USD
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price241.16
CurrencyUSD
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX1
BB Medtech HB CHF
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price222.66
CurrencyCHF
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMSS5
BB Medtech HB EUR
Initial charge-
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.31%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price264.57
CurrencyEUR
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMSS4
BB Medtech I CHF
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.56%
Total expense ratio (TER)1.56%
Bid price-
Offer price-
Mid price246.73
CurrencyCHF
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX3
BB Medtech I EUR
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.57%
Bid price-
Offer price-
Mid price347.64
CurrencyEUR
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX4
BB Medtech I GBP
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.56%
Total expense ratio (TER)1.56%
Bid price-
Offer price-
Mid price276.52
CurrencyGBP
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi code10KJ
BB Medtech I USD
Initial charge-
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.57%
Total expense ratio (TER)1.57%
Bid price-
Offer price-
Mid price253.96
CurrencyUSD
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTX5
BB Medtech T CHF
Initial charge-
Annual charge1.2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.91%
Total expense ratio (TER)1.91%
Bid price-
Offer price-
Mid price87.97
CurrencyCHF
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTX6
BB Medtech T EUR
Initial charge-
Annual charge1.2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.91%
Total expense ratio (TER)1.91%
Bid price-
Offer price-
Mid price82.43
CurrencyEUR
Price updated13/01/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGSK9
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.